Keyphrases
Denmark
100%
Vancomycin-resistant Enterococci
74%
Enterococcus Faecium
43%
Methicillin-resistant Staphylococcus Aureus
39%
VanA
35%
Fosfomycin
34%
VanB
32%
Escherichia Coli
29%
Metronidazole
28%
Antibiotics
26%
Carbapenemase-producing
24%
Enterococcus
20%
Whole Genome Sequencing
20%
Vancomycin
19%
Core Genome multilocus Sequence Typing (cgMLST)
18%
Urinary Tract Infection
17%
Intraperitoneal Administration
16%
Antibiotic Use
16%
Appendicitis
16%
Vancomycin Resistance
14%
Elderly People
13%
Appendectomy
13%
Community-acquired Infections
13%
Decolonization
13%
Genotype
13%
Norovirus
13%
Iceland
13%
OXA-48
13%
Primary Care
13%
Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
13%
Copenhagen
12%
Bloodstream Infection
12%
University Hospital
11%
Uncomplicated Appendicitis
10%
Capital Region
10%
Risk Factors
10%
Mecillinam
10%
Diagnostic Accuracy
10%
Epidemiology
10%
Microorganisms
9%
Adult Patients
9%
General Practice
9%
Adverse Events
9%
BlaZ Gene
9%
Hospital Outbreak
8%
Health Systems
8%
Length of Stay
8%
Prophylactic Antibiotics
8%
Bacteremia
8%
Diarrhea
8%
Medicine and Dentistry
Vancomycin Resistant Enterococcus
33%
Infection
24%
Antibiotics
22%
Fosfomycin
20%
Escherichia coli
20%
Enterococcus faecium
20%
Carbapenemase
19%
Methicillin Resistant Staphylococcus Aureus
19%
Appendicitis
18%
Systematic Review
17%
Diagnosis
16%
Metronidazole
15%
Vancomycin
13%
Polymerase Chain Reaction
13%
Adverse Event
13%
Multilocus Sequence Typing
10%
Clinical Trial
10%
Urinary Tract Infection
10%
Antibiotic Therapy
9%
Intraperitoneal Drug Administration
9%
Yersinia
9%
Cohort Effect
9%
Appendectomy
9%
Granulocyte Macrophage Colony Stimulating Factor
9%
Health Care
8%
Diarrhea
8%
Retrospective Study
8%
Bacteremia
8%
Meta-Analysis
7%
Chlorhexidine
7%
Genome Sequencing
7%
Case-Control Study
7%
Disease
7%
Bloodstream Infection
6%
Randomized Controlled Trial
6%
Targeted Therapy
6%
Cohort Study
6%
Natural Orifice Translumenal Endoscopic Surgery
6%
Mesenteric Lymphadenitis
6%
Yersinia Infection
6%
Community Acquired Infection
6%
Hernioplasty
6%
General Medicine
6%
Primary Health Care
6%
Enterococcal Infection
6%
Elderly Population
6%
Emergency Department
6%
RNA 18S
6%
Lactam
6%
Mecillinam
6%
Pharmacology, Toxicology and Pharmaceutical Science
Fosfomycin
34%
Infection
31%
Vancomycin-Resistant Enterococcus
30%
Metronidazole
28%
Antibiotics
25%
Antibiotic Agent
22%
Appendicitis
22%
Enterococcus faecium
21%
Antiinfective Agent
18%
Vancomycin
17%
Carbapenemase
16%
Granulocyte Macrophage Colony Stimulating Factor
16%
Methicillin-Resistant Staphylococcus Aureus
13%
Community Acquired Infection
13%
Cohort Study
13%
Norovirus
13%
Adverse Event
13%
Urinary Tract Infection
9%
Bloodstream Infection
9%
Escherichia coli
9%
Clinical Trial
9%
Retrospective Study
8%
Diarrhea
8%
Case-Control Study
7%
Clindamycin
6%
Cosmetic
6%
Sepsis
6%
Molgramostim
6%
Epidemiology
6%
RNA 18S
6%
Enterococcal Infection
6%
Carbapenem
6%
Placebo
6%
Enterobacter
6%
Pharmacokinetics
6%
Candidemia
6%
Enterobacteriaceae
6%
Fluconazole
6%
Antibacterial Activity
6%
Microorganism
6%
Randomized Controlled Trial
6%
Penicillinase
6%
Dicloxacillin
6%
Norovirus Infection
6%
Enterococcus
5%
